[1] Massimino M, Biassoni V, Gandola L, et al. Childhood medulloblastoma[J]. Crit Rev Oncol Hematol, 2016,105:35-51. [2] Dubuc A M, Northcott P A, Mack S, et al. The genetics of pediatric brain tumors[J]. Curr Neurol Neurosci Rep, 2010, 10(3):215-223. [3] Aref D, Croul S. Medulloblastoma:recurrence and metastasis[J]. CNS oncol,2013,2(4):377-385. [4] Koschmann C, Bloom K, Upadhyaya S, et al. Survival after relapse of medulloblastoma[J]. J Pediatr Hematol Oncol, 2016, 38(4):269-273. [5] 宋飞, 许百男, 张军. 髓母细胞瘤复发、播散性种植及预后的相关因素分析[J]. 临床神经外科杂志, 2014, 11(3):193-196. [6] Nikitovic M, Golubicic I. Treatment options for childhood medulloblastoma[J]. Vojnosanit Pregl, 2013, 70(8):773-777. [7] 李丽丽, 李红星, 彭肖肖, 等. 放化疗与单纯放疗对髓母细胞瘤患者术后疗效比较的Meta分析[J]. 中华临床医师杂志, 2013, 7(19):8809-8813. [8] Rutkowski S, von Hoff K, Emser A, et al. Survival and prognostic factors of early childhood medulloblastoma:an international meta analysis[J]. J Clin Oncol, 2010, 28(33):4961-4968. [9] Dufour C, Kieffer V, Varlet P, et al. Tandem high-dose chemotherapy and autologous stem cell rescue in childrenwith newly diagnosed high-risk medulloblastoma or supratentorial primitive neuro-ectodermic tumors[J]. Pediatr Blood Cancer, 2014,61(8):1398-1402. [10] 王计伟, 陈步东, 杨玉山等.成人髓母细胞瘤患者脑(脊)膜播散种植的诊断与治疗[J]. 中国现代神经疾病杂志, 2015, 15(10):826-830. [11] Yeom K W, Mobley B C, Lober R M, et al. Distinctive MRI features of pediatric medulloblastoma subtypes[J]. AJR Am J Roentgenol,2013,200(4):895-903. [12] Ozerov S S, Tereshchenko G V, Artemov A V, et al. MRI diagnosis of spinal metastasis of medulloblastoma. A clinical case and literature review[J]. Zh Vopr neirokhir Im N N Burdenko, 2015,79(5):72-76. [13] 左丽,李静文,孙立,等.髓母细胞瘤组织MEF2C表达与预后相关性分析[J].中华肿瘤防治杂志,2014,21(3):201-210. [14] Nabors L B, Portnow J, Ammirati M, et al. NCCN Guidelines Insights:Central Nervous System Cancers, Version 1.2017[J].J Natl Compr Canc Netw,2017,15(11):1331-1345. [15] 刘海龙, 曲彦明, 于春江. 鞘内注射治疗髓母细胞瘤研究进展[J]. 中华脑科疾病与康复杂志, 2014, 4(4):38-40. [16] Pompe R S, von Bueren A O, Mynarek M, et al. Intraventricular methotrexate as part of primary therapy for children with infant and/or metastatic medulloblastoma:Feasibility, acute toxicity and evidence for efficacy[J]. Eur J Cancer, 2015, 51(17):2634-2642. [17] Conroy S, Garnett M, Vloeberghs M, et al. Medulloblastoma in childhood:revisiting intrathecal therapy in infants and children[J].Cancer Chemother Pharmacol, 2010, 65(6):1173-1189. [18] Packer R J, Goldwein J, Nicholson H S, et al. Treatment of children with medulloblastomas with reduced-dose craniospinal radiation therapy and adjuvant chemotherapy:A Children's Cancer Group Study[J]. J Clin Oncol, 1999, 17(7):2127-2136. [19] 卜俊国, 郭燕舞, 肖明星,等. 三维适形放疗同期鞘内注射化疗后全身化疗治疗高危髓母细胞瘤[J]. 中华神经医学杂志, 2012, 11(8):788-791. [20] Gandola L,Massimino M,Cefalo G,et al.Hyperfractionated accelerated radiotherapy in the Milan strategy for metastatic medulloblastoma[J].J Clin Oncol,2009,27(4):566-571. [21] MacDonald T J, Aguilera D, Castellino R C, et al. The rationale for targeted therapies in medulloblastoma[J]. Neuro Oncol, 2014, 16(1):9-20. |